Stock Track | Arrowhead Pharmaceuticals Soars 5.49% on Analyst Upgrades and Strategic Developments

Stock Track

Yesterday

Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.

Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $48 from $45, maintaining an Equal Weight rating. The adjustment reflects optimism around the company's growth prospects, particularly with the Redemplo launch and advancements in obesity treatments.

Additionally, TD Cowen analyst Joseph Thome reiterated a Buy rating on the stock, citing promising growth and strategic initiatives. These developments have bolstered investor confidence, contributing to the stock's upward movement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1179190404"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179190404\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179190404?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179190404","market":"hk","top_or_hot":-1,"title":"Stock Track | Arrowhead Pharmaceuticals Soars 5.49% on Analyst Upgrades and Strategic Developments","media":"Stock Track","content":"<p>Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.</p><p>Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $48 from $45, maintaining an Equal Weight rating. The adjustment reflects optimism around the company's growth prospects, particularly with the Redemplo launch and advancements in obesity treatments.</p><p>Additionally, TD Cowen analyst Joseph Thome reiterated a Buy rating on the stock, citing promising growth and strategic initiatives. These developments have bolstered investor confidence, contributing to the stock's upward movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arrowhead Pharmaceuticals Soars 5.49% on Analyst Upgrades and Strategic Developments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arrowhead Pharmaceuticals Soars 5.49% on Analyst Upgrades and Strategic Developments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-26 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.</p><p>Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $48 from $45, maintaining an Equal Weight rating. The adjustment reflects optimism around the company's growth prospects, particularly with the Redemplo launch and advancements in obesity treatments.</p><p>Additionally, TD Cowen analyst Joseph Thome reiterated a Buy rating on the stock, citing promising growth and strategic initiatives. These developments have bolstered investor confidence, contributing to the stock's upward movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1179190404","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179190404","pubTimestamp":1764167902,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.Morgan Stanley raised its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"个股追踪|Arrowhead Pharmaceuticals因分析师升级和战略发展飙升5.49%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals (ARWR) saw its stock price surge by 5.49% during intraday trading on Wednesday, driven by positive analyst sentiment and strategic developments.Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $48 from $45, maintaining an Equal Weight rating. The adjustment reflects optimism around the company's growth prospects, particularly with the Redemplo launch and advancements in obesity treatments.Additionally, TD Cowen analyst Joseph Thome reiterated a Buy rating on the stock, citing promising growth and strategic initiatives. These developments have bolstered investor confidence, contributing to the stock's upward movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}